-
Company Profile for Neuraptive Therapeutics, Inc.
Company Profile for Neuraptive Therapeutics, Inc.
Share
--(BUSINESS WIRE)--Neuraptive Therapeutics, Inc. is a biotechnology company dedicated to developing novel therapeutics and medical products to address the unmet needs of physicians and patients impacted by peripheral nerve injuries.
Company: |
Neuraptive Therapeutics, Inc. |
||
|
|
||
Headquarters Address: |
2 Logan Square |
||
|
Suite 1930 |
||
|
Philadelphia, PA 19103 |
||
|
|
||
Main Telephone: |
617-794-6442 |
||
|
|
||
Website: |
|||
|
|
||
Type of Organization: |
Private |
||
|
|
||
Industry: |
Biotechnology |
||
|
|
||
Key Executives: |
EVP, Head of R&D: Evan Tzanis |
||
|
|
||
EVP, Head of R&D |
|
||
Contact: |
Evan Tzanis |
||
Phone: |
617-794-6442 |
||
Email: |
More News From Neuraptive Therapeutics, Inc.
Neuraptive Therapeutics, Inc. Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating the Safety and Efficacy of NTX-001 Compared to Standard of Care in the Treatment of Upper Extremity Transected Nerves Requiring Surgical Repair
CHESTERBROOK, Pa.--(BUSINESS WIRE)--Neuraptive Therapeutics, Inc. Announces First Patient Enrolled in Phase 3 Clinical Trial...
Neuraptive Therapeutics Announces Presentation of Phase 2 Topline Interim Results for NTX-001 at the 2024 American Society for Surgery of the Hand (ASSH) Annual Meeting
CHESTERBROOK, Pa.--(BUSINESS WIRE)--Neuraptive Therapeutics Inc., a leading biopharmaceutical company focused on novel treatments for peripheral nerve injuries, today announced that interim topline results from its ongoing Phase 2 NEUROFUSE Study will be presented at the 2024 American Society for Surgery of the Hand (ASSH) Annual Meeting, held September 19-21 in Minneapolis, MN. The presentation, titled Safety and Efficacy of NTX-001 in the Treatment of Acute Single Transected Peripheral Nerve...
Neuraptive Therapeutics Receives FDA Breakthrough Therapy Designation for NTX-001 and Provides Update on the Advancements of NTX-001 for the Treatment of Peripheral Nerve Injury Requiring Repair
CHESTERBROOK, Pa.--(BUSINESS WIRE)--Neuraptive Therapeutics, Inc. today announced that NTX-001 has been granted Breakthrough Therapy Designation, thus providing the potential for accelerated development for patients with peripheral nerve injury requiring repair. This designation follows the results from the Phase 2 NEUROFUSE study and several interactions with the FDA. NTX-001 has the potential to be a groundbreaking therapy in the field of nerve repair. Neuraptive is preparing to launch a Phas...
